SPH Stock Overview
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, infusion medicine, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sopharma AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв13.05 |
| 52 Week High | лв18.90 |
| 52 Week Low | лв10.70 |
| Beta | -0.053 |
| 1 Month Change | -6.45% |
| 3 Month Change | -10.00% |
| 1 Year Change | -4.04% |
| 3 Year Change | 63.13% |
| 5 Year Change | 57.23% |
| Change since IPO | 74.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| SPH | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -3.7% | 0.06% | 1.4% |
| 1Y | -4.0% | -3.1% | 26.6% |
Return vs Industry: SPH matched the Polish Pharmaceuticals industry which returned -3.9% over the past year.
Return vs Market: SPH underperformed the Polish Market which returned 27.4% over the past year.
Price Volatility
| SPH volatility | |
|---|---|
| SPH Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.8% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: SPH has not had significant price volatility in the past 3 months.
Volatility Over Time: SPH's weekly volatility has decreased from 12% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 4,721 | Ognian Donev | www.sopharmagroup.com |
Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, infusion medicine, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company’s products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of the reproductive system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions.
Sopharma AD Fundamentals Summary
| SPH fundamental statistics | |
|---|---|
| Market cap | zł2.15b |
| Earnings (TTM) | zł210.95m |
| Revenue (TTM) | zł4.18b |
10.4x
P/E Ratio0.5x
P/S RatioIs SPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPH income statement (TTM) | |
|---|---|
| Revenue | лв1.89b |
| Cost of Revenue | лв1.47b |
| Gross Profit | лв415.51m |
| Other Expenses | лв320.30m |
| Earnings | лв95.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 22.01% |
| Net Profit Margin | 5.04% |
| Debt/Equity Ratio | 34.9% |
How did SPH perform over the long term?
See historical performance and comparison